chemXplore tracks 21 projects in Canada, of which 20 are active.
15 new construction, 4 expansion, and 1 revamp / retrofit.
Expected to start operating, per year; 5 of the active projects carry no start-up date yet.
Owners and developers: Evonik Industries AG (2), Expander Energy Inc. (2), Nouveau Monde Graphite Inc. (2), Pembina Pipeline Corporation (2), Aluminerie Alouette Inc. (1), Asahi Kasei Corporation (1)
Investors: Canada Growth Fund Inc. (2), Eni S.p.A. (2), Investissement Québec (2), Evonik Industries AG (1), Export Development Canada (1), Honda Motor Co., Ltd. (1)
Contractors, licensors, and offtakers are recorded on 17 of these 20 projects For subscribers
Targeting: Carbon dioxide (4), Graphene (4), Sustainable Aviation Fuel (4), Urea (3), Natural gas (2), Ammonia (1)
FDA clears once‑weekly basal insulin that reduces injection frequency vs daily therapy; Phase 3 QWINT trials in >3,400 adults showed non‑inferior A1C vs glargine and degludec.
Aligns businesses by role, assigns roles to six German sites, and shifts investment to Asia/Americas; launches growth projects in Canada and Slovakia, funded by cost cuts.
Adds ~370 kboe/d production, targets ~4% CAGR to 2030; equity value ~US$13.9bn and enterprise value ~US$16.5bn; funded by US$3.3bn cash and US$10.6bn new shares.
FT liquids upgrading tech to convert cellulosic feedstock into drop-in SAF and renewable diesel; initial deployment at two Canadian facilities; FID targeted December 2026.
Pre‑specified VESALIUS‑CV analysis shows evolocumab plus background therapy lowers deaths and major CV events in high‑risk adults without prior MI/stroke.
New plant adds clinical-scale lipid nanoparticle drug product capacity with federal support; production is planned to start at the end of 2029.
Phase 3 CROSSING shows histologic remission and improved dysphagia at week 24 with benefits sustained through week 52 in symptomatic, uncontrolled eosinophilic esophagitis.
New Charlotte coating line adds regional wet-process separator capacity; commercial output planned H2 fiscal 2026 and will pair with a planned Canadian plant.
Portfolio concentrated into fewer countries, expected ~USD 20bn free cash flow 2026–2030; US, Brazil and Angola to drive growth; higher margins from high-grading and stepped-up exploration.
Contracts fund urea licensing, PDP and proprietary equipment across Asia, Europe and North America, plus a feasibility study for a 40,000 t/yr polyolefin upcycling plant.
